1. ALLA AKTIER
  2. NYHETER
  3. MAGLE CHEMOSWED

Magle Chemoswed

Nyheter Magle Chemoswed Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Magle Group successfully places senior secured bonds of SEK 350 million

MAR

Magle Chemoswed Holding AB (publ) ("Magle Group") has today successfully placed senior secured bonds in an amount of SEK 350 million with a tenor of three years (the "Bonds"). The Bonds will carry floating rate interest of STIBOR 3m plus 6.50 per cent. per annum and will be issued at 97 per cent. of par value. The issue date for the Bonds is expected to be on or about 4 July 2025.

The net proceeds from the Bonds will be used to refinance existing debt and for general corporate purposes, including investments, acquisitions and capital expenditure.
 
The Bonds will be listed on a regulated market within twelve months and Nasdaq Transfer Market within 60 days (with the intention to list within 30 days).
 
Pareto Securities acted as Sole Bookrunner, Advokatfirman Schjødt acted as legal advisor to Magle Group, and Roschier Advokatbyrå acted as legal advisor to Pareto Securities in connection with the bond issue. Vator Securities acted as financial advisor to Magle Group.

Contacts Justin & Aaron

Justin Pierce, CEO, phone +46 (0)70 593 58 21, justin.pierce@maglechemoswed.com

Aaron Wong, CFO, phone +46 (0)76 664 35 79, aaron.wong@maglegroup.com

About Us

The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Magle Biopolymers A/S- a specialized manufacturing organization of Dextran technology. Learn more on www.maglechemoswed.com and www.maglegroup.com and www.maglepharmacept.com and www.maglebiopolymers.com

Vator Securities is the Company's certified adviser on Nasdaq First North Growth Market and can be reached at ca@vatorsec.se or +46 (0)8-580 065 99.

This information is information that Magle Chemoswed is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-06-24 17:20 CEST.

Attachments

Magle Group successfully places senior secured bonds of SEK 350 million

Datum 2025-06-24, kl 17:20
Källa MFN
Bifogade filer
Magle Group successfully places senior secured bonds of SEK 350 million